Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Solriamfetol Action Pathway
Homo sapiens
Drug Action Pathway
Solriamfetol, also known as Sunosi, is a dopamine and norepinephrine reuptake inhibitor (DNRI). This drug is indicated for the daytime treatment of sleepiness associated with narcolepsy or obstructive sleep apnea. Solriamfetol was given FDA approval in 2019. Solriamfetol weakly binds to dopamine and norepinephrine transporters but not serotonin transporters. Those transporters are called sodium-dependent dopamine transporter and sodium-dependent noradrenaline transporter. This makes more dopamine and noradrenaline available in the synapses of the brain. In consequence, the postsynaptic has more of those neurotransmitters available. Norepinephrine and dopamine are important neurotransmitters in sleep-wake regulation. This drug is available as oral tablets.
References
Solriamfetol Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Amsterdam JD, Brunswick DJ, Hundert M: A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A--a putative, new antidepressant. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1333-8. doi: 10.1016/s0278-5846(02)00298-1.
Pubmed: 12502022
Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.
Pubmed: 29891587
Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP: Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431. doi: 10.1164/rccm.201806-1100OC.
Pubmed: 30521757
Zomorodi K, Kankam M, Lu Y: A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Clin Ther. 2019 Feb;41(2):196-204. doi: 10.1016/j.clinthera.2018.12.001. Epub 2018 Dec 28.
Pubmed: 30598342
Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A: Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.
Pubmed: 29891587
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings